This website is intended for healthcare professionals only
User log in




  
February 2020

GINA clarifies MART recommendations



Misinterpretation by some clinicians of the 2019 Global Initiative for Asthma (GINA) recommendations for patients on combination inhaled corticosteroids/long acting b2-agonists (ICS/LABA) has prompted the organisation to issue clarification.

In the GINA 2019 treatment algorithm for adults and adolescents, Steps 3-5 show the medication options for patients with moderate to severe asthma in whom modifiable causes of symptoms or exacerbations have been addressed. In these patients, low-dose ICS-formoterol is the preferred reliever only for patients who are prescribed maintenance and reliever therapy with ICS-formoterol.

GINA does not recommend use of ICS-formoterol as the reliever for patients taking combination ICS-LABA medications with a different LABA. For these patients, their as-needed reliever inhaler should be a short-acting b2-agonist (SABA).

The maintenance and reliever regimen (sometimes called ‘MART’ or ‘SMART’) is approved in many countries for use with low dose beclometasone-formoterol or low dose budesonide-formoterol. With this regimen, the patient receives ICS-formoterol as their regular twice-daily or once-daily maintenance treatment, and takes additional doses of a low-dose ICS-formoterol for relief of symptoms, instead of as-needed short-acting b2-agonist.

GINA states: ‘In adult and adolescent patients with ≥1 exacerbation in the previous year, the ICS-formoterol maintenance and reliever regimen significantly reduces exacerbations and provides similar levels of asthma control at relatively low doses of ICS, compared with a fixed dose of ICS-LABA as maintenance treatment or a higher dose of ICS, both with as-needed SABA. Low dose ICS-formoterol is the preferred reliever for patients prescribed the maintenance and reliever treatment regimen. It should not be used as the reliever for patients taking combination ICS-LABA medications with a different LABA.’


GINA Alert. https://ginasthma.org/gina-2019-recommendations-about-reliever-medications-in-steps-3-5/